eFFECTOR Therapeutics
Protein Translation Inhibitors for Oncology

eFFECTOR Therapeutics is pioneering a new class of therapeutics known as selective translation regulators (STRs). By acting on key biological mechanisms responsible for tumor growth and immune suppression, STRs represent a promising small molecule approach for fighting cancer. Their most advanced program, tomivosertib (eFT508), is currently in multiple Phase 2 clinical trials for the treatment of several types of cancer, both as an immune modulator and as an agent that acts directly on tumor cells. NASDAQ: EFTR

 

 


University
UC San Francisco
Sector
Life Science
Status
Public
Initial Investment Stage
Early
View Website